...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity
【24h】

Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity

机译:发现2伊恶唑-3-基 - 乙酰胺类似物,作为热休克蛋白90(HSP90)抑制剂,具有显着的抗HIV活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The recent burst of explorations on heat shock protein 90 (HSP90) in virus research supports its emergence as a promising target to overcome the drawbacks of current antiviral therapeutic regimen. In continuation of our efforts towards the discovery of novel anti-retroviral molecules, we designed, synthesized fifteen novels 2-isoxazol-3-yl-acetamide based compounds (2a-o) followed by analysis of their anti-HIV activity and cytotoxicity studies. 2a-b, 2e, 2j, and 2l-m were found to be active with inhibitory potentials >80% at their highest non-cytotoxic concentration (HNC). Further characterization of anti-HIV activity of these molecules suggests that 21 has similar to 3.5 fold better therapeutic index than AUY922, the second generation HSP90 inhibitor. The anti-HIV activity of 21 is a cell type, virus isolate and viral load independent phenomena. Interestingly, 21 does not significantly modulate viral enzymes like Reverse Transcriptase (RT), Integrase (IN) and Protease (PR) as compared to their known inhibitors in a cell free in vitro assay system at its HNC. Further, 21 mediated inhibition of HSP90 attenuates HIV-1 LTR driven gene expression. Taken together, structural rationale, modeling studies and characterization of biological activities suggest that this novel scaffold can attenuate HIV-1 replication significantly within the host and thus opens a new horizon to develop novel anti-HIV therapeutic candidates. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:近期病毒研究中的热休克蛋白90(HSP90)的探索爆发支持其作为有前途的目标,以克服当前抗病毒治疗方案的缺点。在继续我们对发现新型抗逆转录病毒分子的努力,我们设计了合成的十五个小说2-异恶唑-3-基 - 乙酰胺(2A-O),然后分析了它们的抗HIV活性和细胞毒性研究。发现2A-B,2E,2J和2L-M以最高的非细胞毒性浓度(HNC)为活性> 80%的活性> 80%。进一步表征这些分子的抗HIV活性表明,21类似于3.5倍的治疗指标比Auy922,第二代HSP90抑制剂。抗HIV活性为21是细胞类型,病毒分离物和病毒载荷无关的现象。有趣的是,与其在其HNC的无细体测定系统中的已知抑制剂相比,2121没有显着调节逆转录酶(RT),整合酶(In)和蛋白酶(PR)等病毒酶。此外,21例介导的Hsp90抑制衰减HIV-1 LTR驱动的基因表达。在一起,结构理由,建模研究和生物活动的表征表明,这种新的支架可以在宿主内显着衰减HIV-1复制,从而开启新的地平线以开发新的抗HIV治疗候选者。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号